CLRB News and Press, Cellectar Biosciences Inc.

2024-07-24 15:22:07 ET Cellectar Biosciences, Inc. (CLRB) KOL and Analyst Day Call July 24, 2024, 08:00 AM ET Company Participants James Caruso - President and Chief Executive Officer Sikander Ailawadhi - Professor of Medicine at Mayo Clinic Michael Morris - Co-F...

2024-07-23 15:09:01 ET Summary Cellectar Biosciences, Inc. announced that the primary endpoint was met in the pivotal phase 2 CLOVER WaM study, using iopofosine for the treatment of patients with relapsed/refractory Waldenstrom's Macroglobulinemia or WM. The NDA submission of ipof...

2024-07-23 07:58:48 ET More on Cellectar Biosciences Cellectar Biosciences: Still Working On That Hit (Maintain Buy) Cellectar Biosciences, Inc. 2024 Q1 - Results - Earnings Call Presentation Cellectar Biosciences, Inc. (CLRB) Q1 2024 Earnings Call Transcript ...

56.4% major response rate exceeded 20% primary endpoint 98.2% disease control rate achieved in heavily pretreated patients Responses shown in difficult-to-treat, high-needs patient populations with approximately 27% of patients refractory to all available therapies and 40%...

FLORHAM PARK, N.J., July 22, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the majority of Tranche B warran...

FLORHAM PARK, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it will host an event on July 24, 202...

Opportunity for Iopofosine Expansion Within Areas of High Unmet Need in Non-Hodgkin’s Lymphoma Establishes Partnership With One of the Largest Cancer Research and Treatment Organizations in the U.S. FLORHAM PARK, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences,...

2024-05-24 17:32:09 ET More on Cellectar Biosciences Cellectar Biosciences: Still Working On That Hit (Maintain Buy) Cellectar Biosciences GAAP EPS of -$0.74 misses by $0.18 Seeking Alpha’s Quant Rating on Cellectar Biosciences Read the full article ...

2024-05-21 09:13:41 ET More on Eli Lilly Eli Lilly: Great Time To Divest Before It Potentially Crashes Eli Lilly Remains Expensive Here - Minimal Margin Of Safety Eli Lilly: Don't Overpay For Miracle Drugs Eli Lilly’s tirzepatide cleared for diabetes t...

2024-05-20 13:02:41 ET Summary Cellectar Biosciences, Inc. is focused on developing a radiopharmaceutical for Waldenstrom's macroglobulinemia, a type of non-Hodgkin lymphoma. The company has positive topline data from a pivotal study, with a high response rate in patients with Wal...